Breast Cancer | Specialty

The breast cancer condition center is a comprehensive resource for clinical news and expert insights on breast cancer. Read more at OncLive.

Tailor-Made for a Lifelong Pursuit of Precision in Cancer Care

December 23rd 2024

With a focus on closing gaps in cancer care for underserved populations, Joseph A. Sparano, MD, FACP, always strives to put patients first—a quality that has become a hallmark of his research and career in oncology.

Dr Sardesai on Lasofoxifene Plus Abemaciclib in ESR1-Mutant, ER+/HER2– Breast Cancer

December 19th 2024

Sagar D. Sardesai, MBBS, discusses the phase 3 ELAINE-3 trial evaluating lasofoxifene plus abemaciclib in ESR1-mutant, ER-positive, HER2-negative breast cancer.

Lasofoxifene Aims to Amplify Efficacy of Abemaciclib in ESR1-Mutated ER+/HER2– Metastatic Breast Cancer

December 19th 2024

Lasofoxifene plus abemaciclib is set to be evaluated in ESR1-mutated ER+/HER2– metastatic breast cancer in the phase 3 ELAINEIII trial.

Effects of trastuzumab deruxtecan (T-DXd) on health-related quality of life (HRQOL): DESTINY-Breast12 (DB-12) results

December 18th 2024

Dr. Laura Huppert presents key data from the DESTINY-Breast12 study, showcasing the effects of trastuzumab deruxtecan on health-related quality of life and neurological function in HER2+ metastatic breast cancer patients, with findings demonstrating preserved quality of life and neurological stability, regardless of brain metastasis status.

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS

December 17th 2024

Rates of invasive cancer were noninferior when patients with low-risk ductal carcinoma in situ received active monitoring vs guideline concordant care.

Postoperative Radiation Therapy Improves HRQOL, Safety in Early-Stage HR+/HER2– Breast Cancer

December 16th 2024

Radiation therapy produced superior HRQOL outcomes and fewer toxicities vs endocrine therapy in older patients with stage I luminal-like breast cancer.

Baseline ctDNA Is Associated With Larger Pathological Tumors in HR+ Early Breast Cancer

December 16th 2024

Ultra-sensitive tissue-free ctDNA testing showed that baseline ctDNA was associated with larger pathological tumor size in HR-positive breast cancer.

Elacestrant Improves Real-World Time to Next Treatment or Treatment Discontinuation in ESR1+ HR+/HER2– Breast Cancer

December 15th 2024

Elacestrant increased real-world TTNT for patients with ESR1-mutant HR-positive/HER2-negative breast cancer vs PFS from the phase 3 EMERALD trial.

The OncFive: Top Oncology Articles for the Week of 12/8

December 14th 2024

Fixed-duration acalabrutinib combination improves PFS in CLL, imlunestrant ± abemaciclib boosts PFS in ESR1-mutated ER+ breast cancer, and more.

ICIs Result in Increased Rates of High-Grade irAEs for Older Patients With Breast Cancer

December 14th 2024

The risk of developing high-grade immune-related AEs was heightened among patients with breast cancer who were older and who had chronic kidney disease.

Dr Grinshpun on Ultra-Sensitive ctDNA Detection in HR+ Early Breast Cancer

December 14th 2024

Albert Grinshpun, MD, MSc, discusses the utility of ctDNA as a predictive biomarker of endocrine therapy sensitivity in patients with HR+ breast cancer.

Dr Mayer on Niraparib Plus Dostarlimab in ER+ BRCA/PALB2-Mutated Breast Cancer

December 14th 2024

Erica L. Mayer, MD, MPH, discusses findings with neoadjuvant niraparib plus dostarlimab in ER-positive, HER2-negative, BRCA/PALB2-mutated breast cancer.

Recurrence-Free Interval Is Longer With Low ctDNA Levels at Baseline in TNBC

December 13th 2024

ctDNA was most frequently detected within 6 months post-treatment in patients with TNBC, aligning with the early recurrence pattern characteristic of the disease.

Perioperative Atezolizumab Plus Chemo Does Not Improve EFS in TNBC

December 13th 2024

Treatment with atezolizumab and neoadjuvant chemotherapy followed by adjuvant atezolizumab did not improve EFS in triple-negative breast cancer.

Neoadjuvant Niraparib Plus Dostarlimab Generates pCRs in BRCA+ ER+/HER2– Breast Cancer

December 13th 2024

Treatment with preoperative niraparib plus dostarlimab generated responses among patients with BRCA-mutant, ER-positive, HER2-negative breast cancer

Camrelizumab/Chemo Could Represent New Neoadjuvant Option in Early or Locally Advanced TNBC

December 13th 2024

Neoadjuvant camrelizumab paired with chemotherapy significantly improved pCR over chemotherapy alone in early or locally advanced TNBC.

Wrapping up the Pivotal Highlights From SABCS 2024 With Drs Bora Lim and Stephanie Graff

December 13th 2024

Bora Lim, MD, of The University of Texas MD Anderson Cancer, and Stephanie Graff, MD, of Brown University Health, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Dr Rozenblit on Pembrolizumab Outcomes by TMB Status in HR+ Metastatic Breast Cancer

December 13th 2024

Mariya Rozenblit, MD, discusses how genomic alterations and TMB influence the efficacy of immune checkpoint inhibitors in HR+ metastatic breast cancer.

Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcomes in HR+ Advanced Breast Cancer

December 13th 2024

Maxwell Lloyd, MD, discusses a real-world study of elacestrant outcomes based on prior treatment and ESR1 mutation status in HR+ breast cancer.

Palbociclib Plus Anti-HER2 and Endocrine Therapy Prolongs PFS in HR+/HER2+ Breast Cancer

December 12th 2024

Palbociclib plus anti-HER2 and endocrine therapy improved progression-free survival in hormone receptor–positive, HER2-positive metastatic breast cancer.